Trials / Completed
CompletedNCT03506854
Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study Of ISIS 681257 Subcutaneous Injections In Male And Female Subjects With Normal And Impaired Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Akcea Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study of ISIS 681257 Subcutaneous Injections in Male And Female Subjects with Normal and Impaired Renal Function
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS 681257 | Xmg dose administered as a subcutaneous injection |
Timeline
- Start date
- 2018-03-20
- Primary completion
- 2018-10-11
- Completion
- 2018-10-11
- First posted
- 2018-04-24
- Last updated
- 2019-05-22
Locations
3 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03506854. Inclusion in this directory is not an endorsement.